Device – Drug Combinations: Practical Guidance on Borderline Issues and the Consultation Process

This one day course has been designed to provide manufacturers with the knowledge and skills to interpret the requirements of the drug consultation process for devices containing ancillary medicinal substances.

This in-house course focuses on determination of the applicable European legislation for borderline products, and provides insight into further information and guidance related to the distinction between medical devices and medicinal products. This course also examines devices incorporating derivatives of human blood or plasma.

Unsure if this course is for you? Watch our complimentary taster webinar.

Who should attend?

Medical device and pharmaceutical:  

  • Professionals working in Regulatory Affairs
  • Research and development
  • Consultants
  • Project managers and any staff involved in the product to market process

Participants should have experience and/or a basic knowledge of either pharmaceutical or medical device product development, together with an awareness of the Medical Device Directive 93/42/EEC or pharmaceutical legislation Directive 2001/83/EC.

This course is provided in-company only. Contact us for a quote.

“The tutor undertook the course with enthusiasm, and allowed each group member to provide input into the day.”

What will I learn?

On completion of this training, participants will be able to:  

  • Differentiate between a medical device and medicinal product in terms of classification
  • Introduce and explain the key stages involved in the consultation process
  • Guide a product development team through the planning process identifying realistic timescales
  • Explain the consultation documentation requirements
  • Identify common pitfalls and potential competent authority questions in relation to the drug consultation
  • Appreciate notified body expectations in relation to submission documentation
  • Evaluate changes made post CE marking

How will I benefit?

  • Attendance on this course will provide guidance on how to reduce risks and uncertainty in the EU regulatory process
  • Participants will gain an appreciation of the realistic timescales involved for the consultation process and an awareness of common mistakes to avoid, ensuring delays are minimized

What's included?

  • You will gain 8 CPD points on completing the course
  • Provided as in-company training only
  • Training course notes